Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 274971
— the use of phytoecdysones in the preparation of a composition to act on metabolic syndrome – Patent family No. S1 metabolic syndrome;
— the use of phytoecdysones in stabilizing weight in overweight or obese subjects after dieting – Patent family No. S2 weight stabilization;
— the use of phytoecdysones to improve muscular quality in obese and/or sarcopenic mammals – Patent family No. S3 muscular quality;
— a process whereby new chemical entities are used in the preparation of medicines – Patent family No. S4 phytoecdysone analogue;
— a process for extracting purified 20-hydroxyecdysone and the therapeutic use of these extracts to improve muscle function or treat cardiovascular disease – Patent family No. S5 20-hydroxyecdysone; extracts;
— the use of 20-hydroxyecdysone components and their derivatives to treat myopathies and other muscular dystrophies – Patent family No. S6 20-hydroxyecdysone;
— the use of phytoecdysones to prevent loss of muscular strength after immobilization – Patent family No. S7 Loss of muscle strength.
IPSCIO Record ID: 275007
— the use of a composition of bixin and norbixin to protect the skin against sun damage – Patent family No. M I Photo-protection;
— the use of bixin and norbixin compounds to protect the eye against AMD – Patent family No. M II AMD;
— the use of a composition using norbixin in the treatment of AMD – Patent family No. M III Composition for protecting retinal epithelial cells; and
— the use of compounds from the family of flavonoids and anthocyanidins for the treatment, prevention and/or stabilization of AMD and/or Stargardts disease, pigmentary retinopathy and/or diabetic retinopathy – Patent family MIV Use of 3-deoxyanthocyanidins for the treatment of eye diseases.
IPSCIO Record ID: 271451
The Parties also agree hereby on the financial compensation for the assignment by Assignor to Assignee and/or its Affiliates of any rights on and to Future Results including any rights as a co-inventor of patentable inventions to be covered by Future Patent Applications.
The provisions of this Agreement shall only apply to Results generated by Assignor during the period ending on the earlier of (i) the term of this Agreement and (ii) the Employment Period.
No. 2. The French patent application nÂ°FR1758071 filed on May, 31st 2017 and entitled â€œUse of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathiesâ€.
No. 3. The French patent application nÂ°FR1851778 filed on February, 28th 2018 and entitled â€œPhytoecdysones for their use in the prevention of the loss of muscular strength during an immobilisationâ€ .
No. 4. The French patent application nÂ°FR 1902726, entitled â€œPhytoecdysones and their derivatives for their use in the treatment of neuromuscular diseases â€œ.
No. 5. The French patent application nÂ°FR 1902727, entitled â€œPhytoecdysones and their derivatives for their use in the treatment of alterations of the respiratory functionâ€.
The myopathies are neuromuscular disorders in which the primary symptom is muscle weakness due to dysfunction of muscle fiber.
IPSCIO Record ID: 27797
Product shall mean the combination of carnitine and leupeptin (and any analogues, conjugates or derivatives thereof) designated by Licensor as the Myodur brand.
Trademark shall mean the Myodur brand as used on and in relation to the Product.
Muscular dystrophy (MD) is a group of muscle diseases that weaken the musculoskeletal system and hamper locomotion. Muscular dystrophies are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue.
US Patent 4,742,081 [carnitine]US Patents 4,866,040, 5,008,288 and 5,876,747 [carnitine, aminocarnitine and cysteic acid (taurine)]US and worldwide Patent application for MYODUR specifically in the field of Muscular Dystrophy